309 related articles for article (PubMed ID: 34203048)
1. A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes.
Shaikh S; Lee EJ; Ahmad K; Ahmad SS; Lim JH; Choi I
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34203048
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
3. Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Yokoyama H; Haneda M
Front Endocrinol (Lausanne); 2020; 11():214. PubMed ID: 32390941
[No Abstract] [Full Text] [Related]
4. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes.
Power O; Nongonierma AB; Jakeman P; FitzGerald RJ
Proc Nutr Soc; 2014 Feb; 73(1):34-46. PubMed ID: 24131508
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes.
Singh AK; Yadav D; Sharma N; Jin JO
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34207217
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
Dokken B
J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
[TBL] [Abstract][Full Text] [Related]
9. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Singh AK; Jatwa R; Purohit A; Ram H
J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV.
Rohani ; Febrina E; Wahyuni IS; Levita J
Drug Des Devel Ther; 2023; 17():3473-3491. PubMed ID: 38024536
[TBL] [Abstract][Full Text] [Related]
11. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses.
Mohanty IR; Borde M; Kumar C S; Maheshwari U
Phytomedicine; 2019 Apr; 57():158-165. PubMed ID: 30668318
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
Zhao Y; Yang L; Zhou Z
J Diabetes; 2014 Jan; 6(1):21-9. PubMed ID: 23683065
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
16. A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice.
Lu Y; Lu P; Wang Y; Fang X; Wu J; Wang X
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646613
[TBL] [Abstract][Full Text] [Related]
17. Effects of 22 traditional anti-diabetic medicinal plants on DPP-IV enzyme activity and glucose homeostasis in high-fat fed obese diabetic rats.
Ansari P; Hannon-Fletcher MP; Flatt PR; Abdel-Wahab YHA
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33416077
[TBL] [Abstract][Full Text] [Related]
18. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
20. Antidiabetic activity of
Mohanty IR; Kumar CS; Borde M
Indian J Pharmacol; 2021; 53(5):384-387. PubMed ID: 34854407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
